David Huss

CSO at Shape Therapeutics

Speaker

David J. Huss obtained his PhD in Molecular, Cellular and Developmental Biology from The Ohio State University where he established himself as a card-carrying T cell immunologist. During his PhD, exposure to both basic research and clinical and translational medicine ignited David’s interest to pursue a career in the biotech industry.

In his professional career, David has held roles along the entire drug development lifecycle from discovery research to post-approval sales and marketing. David is currently Chief Scientific Officer at ShapeTX and has driven all aspects of the business, including financings, scientific strategy, and business development. His team is developing programmable RNA medicines. Their innovations have caught the attention of pharma and venture capitalists alike. Under David’s leadership, ShapeTX raised $150M and secured multi-billion-dollar research collaborations with Roche and Otsuka Pharmaceutical. Based on these achievements, David received recognition as an Endpoints “20 under 40” selection in 2023.

Prior to ShapeTX, David led a T cell engineering team at Juno Therapeutics. Before Juno, he led preclinical research programs at Biogen and contributed important scientific insights into the Daclizumab and Tecfidera mechanisms of action, resulting in four peer-reviewed publications.